Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

Thomas M. Habermann, Izidore Lossos, Glen Justice, Julie M. Vose, Peter H. Wiernik, Kyle McBride, Kenton Wride, Annette Ervin-Haynes, Kenichi Takeshita, Dennis Pietronigro, Jerome B. Zeldis, Joseph M. Tuscano

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Summary Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a poor prognosis following first relapse. We present a subgroup analysis of an open-label phase II trial investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL. Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression. The primary endpoint was overall response rate (ORR) and secondary endpoints were duration of response, progression-free survival (PFS) and safety. Among 15 patients with MCL with a median disease duration of 5·1 years and a median of four prior treatments, the ORR was 53%. Three patients (20%) had a complete response and 5 (33%) had a partial response. The median duration of response was 13·7 months and median PFS was 5·6 months. Four of five patients who relapsed after transplantation and two of five patients who previously received bortezomib responded to lenalidomide. The most common grade 4 adverse event was thrombocytopenia (13%) and the most common grade 3 adverse events were neutropenia (40%), leucopenia (27%) and thrombocytopenia (20%). In conclusion, oral lenalidomide monotherapy is well tolerated and active in relapsed or refractory MCL.

Original languageEnglish
Pages (from-to)344-349
Number of pages6
JournalBritish Journal of Haematology
Volume145
Issue number3
DOIs
StatePublished - May 1 2009

Fingerprint

Mantle-Cell Lymphoma
Thrombocytopenia
Disease-Free Survival
Safety
Leukopenia
Neutropenia
Non-Hodgkin's Lymphoma
Disease Progression
Transplantation
lenalidomide
Recurrence

Keywords

  • Efficacy
  • Lenalidomide
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. / Habermann, Thomas M.; Lossos, Izidore; Justice, Glen; Vose, Julie M.; Wiernik, Peter H.; McBride, Kyle; Wride, Kenton; Ervin-Haynes, Annette; Takeshita, Kenichi; Pietronigro, Dennis; Zeldis, Jerome B.; Tuscano, Joseph M.

In: British Journal of Haematology, Vol. 145, No. 3, 01.05.2009, p. 344-349.

Research output: Contribution to journalArticle

Habermann, TM, Lossos, I, Justice, G, Vose, JM, Wiernik, PH, McBride, K, Wride, K, Ervin-Haynes, A, Takeshita, K, Pietronigro, D, Zeldis, JB & Tuscano, JM 2009, 'Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma', British Journal of Haematology, vol. 145, no. 3, pp. 344-349. https://doi.org/10.1111/j.1365-2141.2009.07626.x
Habermann, Thomas M. ; Lossos, Izidore ; Justice, Glen ; Vose, Julie M. ; Wiernik, Peter H. ; McBride, Kyle ; Wride, Kenton ; Ervin-Haynes, Annette ; Takeshita, Kenichi ; Pietronigro, Dennis ; Zeldis, Jerome B. ; Tuscano, Joseph M. / Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. In: British Journal of Haematology. 2009 ; Vol. 145, No. 3. pp. 344-349.
@article{3ccbd0a767084e6a81c354c738d65a6d,
title = "Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma",
abstract = "Summary Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a poor prognosis following first relapse. We present a subgroup analysis of an open-label phase II trial investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL. Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression. The primary endpoint was overall response rate (ORR) and secondary endpoints were duration of response, progression-free survival (PFS) and safety. Among 15 patients with MCL with a median disease duration of 5·1 years and a median of four prior treatments, the ORR was 53{\%}. Three patients (20{\%}) had a complete response and 5 (33{\%}) had a partial response. The median duration of response was 13·7 months and median PFS was 5·6 months. Four of five patients who relapsed after transplantation and two of five patients who previously received bortezomib responded to lenalidomide. The most common grade 4 adverse event was thrombocytopenia (13{\%}) and the most common grade 3 adverse events were neutropenia (40{\%}), leucopenia (27{\%}) and thrombocytopenia (20{\%}). In conclusion, oral lenalidomide monotherapy is well tolerated and active in relapsed or refractory MCL.",
keywords = "Efficacy, Lenalidomide, Mantle cell lymphoma, Non-Hodgkin lymphoma, Safety",
author = "Habermann, {Thomas M.} and Izidore Lossos and Glen Justice and Vose, {Julie M.} and Wiernik, {Peter H.} and Kyle McBride and Kenton Wride and Annette Ervin-Haynes and Kenichi Takeshita and Dennis Pietronigro and Zeldis, {Jerome B.} and Tuscano, {Joseph M.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1111/j.1365-2141.2009.07626.x",
language = "English",
volume = "145",
pages = "344--349",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

AU - Habermann, Thomas M.

AU - Lossos, Izidore

AU - Justice, Glen

AU - Vose, Julie M.

AU - Wiernik, Peter H.

AU - McBride, Kyle

AU - Wride, Kenton

AU - Ervin-Haynes, Annette

AU - Takeshita, Kenichi

AU - Pietronigro, Dennis

AU - Zeldis, Jerome B.

AU - Tuscano, Joseph M.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Summary Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a poor prognosis following first relapse. We present a subgroup analysis of an open-label phase II trial investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL. Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression. The primary endpoint was overall response rate (ORR) and secondary endpoints were duration of response, progression-free survival (PFS) and safety. Among 15 patients with MCL with a median disease duration of 5·1 years and a median of four prior treatments, the ORR was 53%. Three patients (20%) had a complete response and 5 (33%) had a partial response. The median duration of response was 13·7 months and median PFS was 5·6 months. Four of five patients who relapsed after transplantation and two of five patients who previously received bortezomib responded to lenalidomide. The most common grade 4 adverse event was thrombocytopenia (13%) and the most common grade 3 adverse events were neutropenia (40%), leucopenia (27%) and thrombocytopenia (20%). In conclusion, oral lenalidomide monotherapy is well tolerated and active in relapsed or refractory MCL.

AB - Summary Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a poor prognosis following first relapse. We present a subgroup analysis of an open-label phase II trial investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL. Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression. The primary endpoint was overall response rate (ORR) and secondary endpoints were duration of response, progression-free survival (PFS) and safety. Among 15 patients with MCL with a median disease duration of 5·1 years and a median of four prior treatments, the ORR was 53%. Three patients (20%) had a complete response and 5 (33%) had a partial response. The median duration of response was 13·7 months and median PFS was 5·6 months. Four of five patients who relapsed after transplantation and two of five patients who previously received bortezomib responded to lenalidomide. The most common grade 4 adverse event was thrombocytopenia (13%) and the most common grade 3 adverse events were neutropenia (40%), leucopenia (27%) and thrombocytopenia (20%). In conclusion, oral lenalidomide monotherapy is well tolerated and active in relapsed or refractory MCL.

KW - Efficacy

KW - Lenalidomide

KW - Mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=64149112784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149112784&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07626.x

DO - 10.1111/j.1365-2141.2009.07626.x

M3 - Article

VL - 145

SP - 344

EP - 349

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -